LVTX LAVA THERAPEUTICS NV

LAVA Announces Annual Meeting of Shareholders

LAVA Announces Annual Meeting of Shareholders

UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2023 (GLOBE NEWSWIRE) -- () (LAVA), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the annual general meeting of shareholders will take place on Wednesday, June 14, 2023 at 2:00 p.m. CEST.

All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are available in the “Investors” section of LAVA’s website () under “Annual Meeting.” The documents will also be made available on the SEC’s website at  Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting.

About LAVA Therapeutics

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. A Phase 1/2a dose escalation clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling in the US and EU (). A Phase 1/2a dose escalation clinical study to evaluate LAVA-051, for the treatment of multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia, is also enrolling patients in the EU and US ().  The Company has a license agreement with Seagen for the development of SGN-EGFRd2 (LAVA-1223).  For more information, please visit , and follow us on , and .

CONTACTS

Investor Relations

Argot Partners (IR/Media)

212-600-1902



EN
30/05/2023

Underlying

LVTXLAVA THERAPEUTICS NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LAVA THERAPEUTICS NV

 PRESS RELEASE
Free
LVTX LAVA THERAPEUTI...

LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent ...

LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq UTRECHT, The Netherlands, and PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today announced that 22,877,463 of LAVA’s common shares, representing approximately 87% of LAVA’s outstanding common shares, were validly tendered and not withdrawn prior to the expiration of the initial offering period one minute after 11:59 p.m. Eastern Time on November 12, 2025. As a result, the minimum tender condition and other conditions of the previously announced tend...

November 13, 2025 1 EN
 PRESS RELEASE
Free
LVTX LAVA THERAPEUTI...

LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for ...

LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to LAVA shareholders related to the proposed transaction with XOMA Royalty Corporation (“XOMA”) (NASDAQ: XOMA). On August 4, 2025, XOMA and LAVA announced they had entered into a share purchase agreement. More recently, on October 17, 2025, XOMA announced it had extended its offer (the “Offer”) to purchase all ou...

November 10, 2025 1 EN
 PRESS RELEASE
Free
LVTX LAVA THERAPEUTI...

LAVA Therapeutics to Move Extraordinary General Meeting to Early Novem...

LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025 Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing the announced acquisition in the fourth quarter of 2025. UTRECHT, The Netherlands and PHILADELPHIA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (the “Company” or “LAVA”) (NASDAQ: LVTX) today announced that the Company has decided to cancel the Extraordinary General Meeting of Shareholders (the “EGM”) scheduled to occ...

September 30, 2025 1 EN
 PRESS RELEASE
Free
LVTX LAVA THERAPEUTI...

LAVA Reports Second Quarter 2025 Financial Results and Provides Corpor...

LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA’s two partnered assets and unpartnered programsConsummation of acquisition expected to occur in the fourth quarter of 2025, subject to customary closing conditions and an extraordinary general meeting of shareholdersAnnounced decision to discontinue development of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome; wind-down of t...

August 13, 2025 1 EN
 PRESS RELEASE
Free
LVTX LAVA THERAPEUTI...

LAVA Reports First Quarter 2025 Financial Results, Provides Business U...

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update Focused on evaluation of strategic alternatives, with restructuring and closure of the Netherlands operationsEnrollment in LAVA-1266 Phase 1 continues to progressCash, cash equivalents and short-term investments of $66.6 million as of March 31, 2025 expected to fund operations into 2027 UTRECHT, The Netherlands and PHILADELPHIA, May 14, 2025 (GLOBE NEWSWIRE) --   (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on its proprietary Gammabody® bispecific gamma delta T cell enga...

May 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch